Kite Pharma CAR-T Therapy Shows Results in Lymphoma Patients

Kite Pharma (KITE) revealed six-month results from a study of its CAR-T therapy in patients with lymphomas, according to TheStreet's Adam Feuerstein. One-third of patients treated with Kite's KTE-C19 saw their tumors disappear. These patients received previous treatments prior to Kite Pharma's, but all proved ineffective. The company expects to file a marketing application for the treatment to the Food and Drug Administration by the end of next month.

Watch More: La Jolla Pharma Drug Raises Blood Pressure in Late-Stage Study of Shock Patients